FDA Authorizes Pfizer-BioNTech's Updated COVID-19 Vaccine for 2026-2027 Season

The U.S. FDA has approved Pfizer and BioNTech's updated COVID-19 vaccine, targeting the XFG variant, for the upcoming respiratory season. This authorization applies to adults aged 65 and older, and individuals aged 5-64 with underlying conditions increasing severe COVID-19 risk. The decision is based on data confirming the vaccine's safety, effectiveness, and ability to generate strong immune responses against current SARS-CoV-2 variants.